AI in Target Identification and Drug Discovery: Transforming the Future of Medicine

Artificial intelligence (AI) is taking a transformative role in target identification and drug discovery. Today, AI algorithms can analyze vast, multi-modal datasets to identify drug targets, accelerate lead compound discovery, and optimize drug design. AI is being used by biotechnology companies around the world to compress timelines and improve clinical trial outcomes.

Join Kimberly Robasky, Associate Director of Machine Learning / AI at Arrakis Therapeutics, to uncover the data-driven revolution in personalized medicine enabled by AI-driven drug development.

Learn more at datascienceconsortium.org.

register

Pragmatic Trial of an EHR Application to Display Real-time PRO Data: Successes and Challenges

This NIH Collaboratory Rethinking Clinical Trials Grand Rounds features:

Gabriela Schmajuk, MD, MS
Professor of Medicine
UCSF and the San Francisco VA

Learn More